

Cite this: *Nanoscale*, 2024, **16**, 20679

# Orotic acid-capped Tb(III)-doped calcium sulphate nanorods for the selective detection of tryptophan†

Jaydeep Kumar,<sup>a</sup> Neha Yadav,<sup>b</sup> Viplove Mishra,<sup>a</sup> Heramba V. S. R. M. Koppiseti,<sup>a</sup> Avishek Roy,<sup>a</sup> Antarip Mitra<sup>a</sup> and Venkataramanan Mahalingam<sup>id</sup>\*<sup>a</sup>

Lanthanide-based luminescent materials have gained huge attention due to their applications in opto-electronic devices, sensing, bio-imaging, anti-counterfeiting, and more. In this work, we report a luminescence-based sensor for the detection of tryptophan using orotic acid-capped Tb<sup>3+</sup>-doped CaSO<sub>4</sub> nanorods (NRs). Orotic acid (OA) was found to play a dual role as a capping agent to control the growth of the nanorods and as a sensitizer for Tb<sup>3+</sup> ions. The resulting nanorods exhibited excellent dispersibility and strong photoluminescence signals characteristic of Tb<sup>3+</sup> ions in the visible region. Nearly 10-fold enhancement in the emission intensity was noted through OA sensitization compared to direct excitation of Tb<sup>3+</sup> ions (acceptors). Interestingly, the strong emission intensity of the NRs reduced significantly with the addition of tryptophan. In contrast, hardly any change was noted with the addition of other amino acids and metal ions, suggesting greater selectivity for tryptophan. Moreover, there is barely any notable interference from other amino acids toward the detection of tryptophan. The limit of detection is found to be ~0.61 μM. Finally, the sensing study was extended to biological samples to detect tryptophan present in blood plasma, urine, and saliva samples. The nanorods demonstrated high detection abilities, indicating the potential of the developed materials for biomedical applications.

Received 4th July 2024,  
Accepted 8th October 2024

DOI: 10.1039/d4nr02774d

rsc.li/nanoscale

## Introduction

Tryptophan is one of the essential aromatic amino acids that has numerous applications in different fields.<sup>1</sup> Its detection can provide crucial insights into the structural and functional properties of biomolecules and also be a suitable biomarker for different diseases, especially in medicine.<sup>2</sup> For instance, tryptophan has been shown to be a precursor for serotonin, a neurotransmitter that regulates mood and sleep patterns.<sup>3</sup> Besides, tryptophan has been used to diagnose and monitor cancer.<sup>4</sup> In certain types of cancer, tryptophan metabolism is altered, leading to increased levels of specific metabolites, like in the case of gastric cancer, where an increased level of tryptophan in gastric juice can be a marker of potential gastric cancer.<sup>5</sup> Hence, the detection of tryptophan can help in the early diagnosis of the disease, which is quite essential in the field of medicine. The free tryptophan level in plasma has

been found to be linked with major depressive disorders (MDD), type 2 diabetes, tryptophan metabolism, *etc.*<sup>6–10</sup> Also, the tryptophan level in saliva was found to be correlated with levels of serotonin, salivary cortisol, *etc.*<sup>11–13</sup> Additionally, tryptophan levels in urine were also reported to be correlated to vitamin B6 deficiency, breast cancer, and autistic patients, just to mention a few.<sup>14–16</sup> The detection of tryptophan is also essential in environmental applications such as monitoring water quality.<sup>17</sup> Since tryptophan is also present in natural organic matter, its presence in organic pollutants can also serve as a marker for microbial activities.<sup>18,19</sup> Adding these up, analyzing tryptophan can provide valuable information in various applications.

Traditional methods for tryptophan detection include mass spectrometry, inductively coupled plasma mass spectrometry (ICP-MS), infrared spectroscopy, gas chromatography, electrochemical methods, AAS, voltammetry, high-performance liquid chromatography (HPLC), and inductively coupled plasma atomic emission spectroscopy (ICP-AES).<sup>20–23</sup> Despite their high sensitivity, they are unsuitable for real-time and on-site detection. Fluorescence-based methods are advantageous as they are relatively simpler and provide high sensitivity, easy sample preparation methods, and quick response times.<sup>24–27</sup> Furthermore, hand-held optical spectrometers are available for on-site detection. There are few reports on fluorescence

<sup>a</sup>Department of Chemical Sciences, Indian Institute of Science Education and Research (IISER) Kolkata, Mohanpur, 741246 West Bengal, India.  
E-mail: mvenkataramanan@yahoo.com

<sup>b</sup>Department of Biological Sciences, Indian Institute of Science Education and Research (IISER) Kolkata, Mohanpur, 741246 West Bengal, India

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4nr02774d>

sensors for the detection of tryptophan. For example, Zhang *et al.* reported a hydrothermally prepared carbon spheres-based fluorescence sensor for detecting L-tryptophan.<sup>28</sup> The carbon spheres have limited capacity in terms of sensing due to challenges associated with achieving precise control over their emission properties. Additionally, the stability and photostability (*i.e.*, resistance to photobleaching) of carbon spheres are not promising, nor do the photophysical properties of the carbon spheres allow them to show low detection limits and sensitivity.<sup>29</sup> In another work, Pang and co-workers have synthesized terbium hybrids with a silica framework to detect tryptophan.<sup>30</sup> However, the obtained detection limit was low, and the synthesis protocol involves multiple complex steps with long reaction times. Alternatively, lanthanide ( $\text{Ln}^{3+}$ )-doped nanomaterials are interesting for the following reasons. For example, the 4f electrons of lanthanides are well-shielded from the 5s and 5p orbitals, making them unperturbed by the surrounding crystal fields.<sup>31,32</sup> This results in quite narrow intra-4f–4f transitions.<sup>33,34</sup> They possess long luminescence lifetimes, allowing efficient excited-state processes like luminescence resonance energy transfer (LRET) to occur.<sup>35,36</sup> LRET can occur over a larger distance in  $\text{Ln}^{3+}$ -doped materials or complexes ( $>10$  nm).<sup>37</sup> This allows efficient sensitization of the  $\text{Ln}^{3+}$  emission, thereby minimizing the problem of low absorbance of  $\text{Ln}^{3+}$  ions. Additionally,  $\text{Ln}^{3+}$  ions show a large Stokes shift, which minimizes optical interference from other foreign molecules.<sup>38,39</sup>

There are quite a few reports on the use of  $\text{Ln}^{3+}$ -doped nanomaterials for the detection of toxic metal ions and other small molecules.<sup>40–50</sup> Nevertheless, there are few reports on using these nanomaterials for amino acid detection, particularly tryptophan. For instance, Hazra *et al.* used  $\text{Tb}^{3+}$ -doped nanocrystals for the detection of aromatic amino acids at nanomolar concentrations.<sup>51</sup> However, the obtained nanocrystals were not selective towards the detection of only tryptophan but rather for all three aromatic amino acids, thus urging the need to develop specific and selective sensor materials. Our objective is to choose a multifunctional ligand that not only controls the nanoparticle size but acts as both a sensitizer to  $\text{Ln}^{3+}$  ions and a linker to tryptophan. The direct binding of tryptophan to the sensitizer is expected to alter the energy transfer efficiency of the latter to the  $\text{Ln}^{3+}$  ions. We have synthesized orotic acid (OA)-capped  $\text{Tb}^{3+}$ -doped  $\text{CaSO}_4$  nanorods (NRs) using a simple microwave method. A 3% doping concentration of  $\text{Tb}^{3+}$  ions was chosen based on optimization results (Fig. S1, ESI†).

The use of microwave synthesis is advantageous due to its fast reaction times, high product yield, and minimal by-products.<sup>52</sup> We have chosen OA as a capping molecule as it possesses a pyrimidinedione unit and the carboxyl group, which can bind to the nanoparticles. The pyrimidinedione unit is expected to have hydrogen bonding interaction with tryptophan. In addition, OA has strong absorbance in the UV region and can thus sensitize the  $\text{Tb}^{3+}$  ions possessing multiple excited energy levels in the UV and visible regions. Interestingly, DMSO plays a dual role as a suitable solvent and

sulphate source.<sup>53</sup>  $\text{CaSO}_4$  is chosen as the host matrix as there is a close match of ionic radii of  $\text{Ca}^{2+}$  ( $1.0 \text{ \AA}$ ) with  $\text{Tb}^{3+}$  ( $0.92 \text{ \AA}$ ), which is expected to facilitate the doping of  $\text{Tb}^{3+}$  ions.<sup>54</sup> The close match in size is essential for preparing  $\text{Tb}^{3+}$ -doped NRs with fewer crystal defects. The successful incorporation of  $\text{Tb}^{3+}$  ions into the  $\text{CaSO}_4$  host matrix resulted in strong green emission upon excitation at 290 nm. The strong intensity of the green emission is attributed to the efficient energy transfer from OA to the  $\text{Tb}^{3+}$  ions.

The addition of tryptophan selectively reduces the emission intensity of the  $\text{Tb}^{3+}$  ions. Furthermore, there is barely any interference in the detection of tryptophan from other amino acids or metal ions. Finally, we have extended the detection of tryptophan using OA-capped  $\text{Tb}^{3+}$ -doped  $\text{CaSO}_4$  NRs in various biological samples.

## Results and discussion

### Phase analysis


Powder X-ray diffraction measurements (PXRD) were performed to check the phase purity of as-prepared  $\text{Tb}^{3+}$ -doped  $\text{CaSO}_4$  nanorods. Fig. 1 shows the PXRD pattern of OA-capped  $\text{CaSO}_4:\text{Tb}^{3+}$  NRs, along with the standard pattern of bulk  $\text{CaSO}_4$ . The PXRD pattern of the NRs matched well with the standard pattern of orthorhombic phase bulk  $\text{CaSO}_4$  (ICDD: 01-072-0916), confirming the formation of orthorhombic phase materials. The observed sharp diffraction peaks indicate good crystallinity in the synthesized NRs.

### Morphology analysis

The formation of the rod-shaped morphology of the OA-capped NRs is confirmed by the field-emission scanning electron microscopy (FESEM) images presented in Fig. 2(a, b, e & f). The formation of rod-shaped nanostructures is further supported by transmission electron microscopy (TEM) analysis



Fig. 1 PXRD pattern of OA@ $\text{CaSO}_4:\text{Tb}^{3+}$  NRs compared with the standard pattern of pure  $\text{CaSO}_4$ .



**Fig. 2** SEM images (a, b, e, and f) and TEM images (c and d) of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs at different magnifications. (g and h) HRTEM image and SAED pattern of the NC NRs showing diffraction planes corresponding to CaSO<sub>4</sub>.

(Fig. 2(c, d, g & h)). The high-resolution TEM image of the OA-CaSO<sub>4</sub> NRs reveals the presence of lattice fringes, suggesting high crystallinity of the NRs. The *d*-spacing between the planes is 2.84 Å, indicating that the observed lattice fringes correspond to the (102) planes.


#### Surface functionalization

FTIR analysis confirmed the binding of OA molecules to the NRs, presumably at the surface. Fig. 3(a) shows the FTIR spectra of pure OA and OA-capped CaSO<sub>4</sub> NRs. The shift in the “C=O” stretching frequency of the –COOH group from 1716 cm<sup>−1</sup> in pure OA to 1623 cm<sup>−1</sup> in OA-capped CaSO<sub>4</sub> indicates the successful binding of OA to the surface of the nano-

rods.<sup>55</sup> This shift is attributed to the binding of the carboxylate group to the NRs through the oxygen atom, leading to a decrease in the strength of the “C=O” bond and a subsequent reduction in the corresponding stretching frequency. The other peaks corresponding to different functional groups remained unaffected, confirming that binding has occurred through the –COOH group.

#### UV-vis and photoluminescence analyses

UV-vis absorption spectra of pure OA and OA-capped CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods are presented in Fig. S2 (ESI<sup>†</sup>). The absorption spectrum of pure OA exhibited a broad peak ranging from 271 to 330 nm, with a maximum at 295 nm. In the case of



**Fig. 3** (a) FT-IR spectra of pure OA and the same after being attached to the Tb<sup>3+</sup>-doped CaSO<sub>4</sub> NRs. (b) Excitation and photoluminescence spectra of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs. The concentration of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods in DMSO used was 1 mg per 10 mL.

OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs, a broad hump with peak maxima at 291 nm is observed, closely resembling the absorption spectrum of pure OA. This confirms the attachment of OA molecules to the nanorods. Fig. 3(b) represents the excitation and emission spectra of OA-capped Tb<sup>3+</sup>-doped CaSO<sub>4</sub> NRs. All PL studies were carried out on the NRs dispersed in DMSO. The PL spectrum shows peaks at approximately 490 nm, 542 nm, 586 nm, and 622 nm, attributed to the <sup>5</sup>D<sub>4</sub> excited level to <sup>7</sup>F<sub>6</sub>, <sup>7</sup>F<sub>5</sub>, <sup>7</sup>F<sub>4</sub>, and <sup>7</sup>F<sub>3</sub> ground state transitions, respectively. A strong band with a maximum at 291 nm is observed in the excitation spectrum ( $\lambda_{em} = 542$  nm, <sup>7</sup>F<sub>5</sub> ← <sup>5</sup>D<sub>4</sub> transition of Tb<sup>3+</sup> ions). The excitation peak position matches with the maxima in the UV-vis absorbance peak of OA, indicating the possible sensitization of the Tb<sup>3+</sup> emission by OA. In comparison with direct excitation (*i.e.*,  $\lambda_{ex} = 378$  nm) of Tb<sup>3+</sup> ions, excitation *via* OA resulted in almost ~10 times enhancement in the emission intensity of Tb<sup>3+</sup> ions.<sup>56</sup> To confirm the occurrence of energy transfer from OA to the Tb<sup>3+</sup> ions inside the NRs, a control experiment was performed by synthesizing citric acid (CA)-capped CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs. CA was chosen as it lacks any characteristic absorption or emission in the UV region and is expected to show hardly any energy transfer process between citric acid and Tb<sup>3+</sup> ions. Fig. S3 (ESI†) shows the comparison of the excitation and PL spectra of Tb<sup>3+</sup>-doped CaSO<sub>4</sub> NRs capped with OA and CA. As expected, barely any enhancement in the characteristic Tb<sup>3+</sup> emission peaks is observed when excited at 291 nm for the CA@CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods compared to the peaks obtained by exciting at 378 nm, which is the direct excitation of the Tb<sup>3+</sup> ions (Fig. S3(c), ESI†).

A schematic of the proposed energy transfer process between OA and Tb<sup>3+</sup> ions in OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods is shown in Fig. S4 (ESI†). Briefly, upon excitation of the NRs at 291 nm, OA becomes excited from the ground state (S<sub>0</sub>) and reaches the excited singlet state (S<sub>1</sub>). This is followed by a non-radiative intersystem crossing (ISC), which results in the long-lived triplet (T<sub>1</sub>) state.<sup>57</sup> The <sup>5</sup>D<sub>4</sub> level of the Tb<sup>3+</sup> ion lies below the triplet state of OA, facilitating energy transfer from the higher triplet state to the low-lying energy levels of Tb<sup>3+</sup> ions. This leads to the population of the excited states of Tb<sup>3+</sup> ions and subsequent radiative transitions from <sup>5</sup>D<sub>4</sub> to <sup>7</sup>F<sub>*J*</sub> (*J* = 3–6) ground state energy levels. The photoluminescence quantum yield was determined using tyrosine as a reference, as its absorbance matches well with that of orotic acid. The quantum yield of OA-capped CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods is calculated using the following equation (eqn (1)):<sup>58</sup>

$$Q_{\text{sample}} = Q_{\text{ref}}(A/A_{\text{ref}})(I_{\text{ref}}/I)(n^2/n_{\text{ref}}^2) \quad (1)$$

where,  $Q_{\text{sample}}$  and  $Q_{\text{ref}}$  are the quantum yields of the nanorods and tyrosine, respectively,  $A$  is the absorbance,  $I$  is the integrated area of photoluminescence peaks, and  $n$  is the refractive index of the solution. The quantum yield of tyrosine as the reference is 0.14.<sup>59</sup> The quantum yield of OA-capped CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods was estimated by comparing the integrated emission spectra of the aqueous solution with that of the tyro-

sine solution. The calculated quantum yield was about 57% for OA-capped CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods.

To investigate the detection capabilities of the OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods, a 1 mM concentration of tryptophan was added to the NR dispersion, and the PL characteristics were measured. A strong reduction in the emission intensity of the Tb<sup>3+</sup> was observed. To understand the selectivity of the detection, a range of different amino acid solutions (at a concentration of 1 mM) were tested.

The results are shown as a bar diagram in Fig. 4a. There is barely any change in the emission intensity with the addition of other amino acids. Additionally, various other analytes are tested, such as EDTA, Cu<sup>2+</sup>, Hg<sup>2+</sup>, Ni<sup>2+</sup>, Mn<sup>4+</sup>, Cd<sup>2+</sup>, Fe<sup>3+</sup>, Zn<sup>2+</sup>, Co<sup>2+</sup>, Pb<sup>2+</sup>, and other relevant cations and anions. Fig. 4b shows a reduction in the emission intensity to approximately 90%, noted only with the addition of tryptophan. The above results confirm the good selectivity of the OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods toward detecting tryptophan.

To understand the reliability of the assay, we have studied the colloidal stability of the nanoprobe. The photoluminescence of the colloidal dispersion was measured up to one hour at 10-minute intervals (Fig. S5, ESI†). The intensity of the OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs showed minimal change, with a maximum decrease of approximately 16% compared to the fresh samples. Please note that all tryptophan detection analyses were done within a minute of addition. This indicates that the nanoprobe exhibits good stability during the assay.

To examine any interference from other amino acids, ions, and molecules towards quenching of the Tb<sup>3+</sup> emission intensity by tryptophan, we conducted PL measurements of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs in a mixture containing equimolar (1 mM) tryptophan and other analytes. The results shown in Fig. 4(c & d) suggest that the quenching of the PL emission intensity by tryptophan is hardly influenced by the presence of other interfering ions and molecules. Furthermore, to check if any change in the pH and temperature of the medium with the addition of different amino acids is responsible for the observed differences in the PL intensity, the pH and temperature of the dispersion containing NRs are measured for the corresponding mixtures. There is barely any noticeable change in the pH and temperature of the NR dispersion in DMSO after adding different amino acids (Fig. S6, ESI†).

To study the photoluminescence response of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs towards tryptophan, different concentrations of tryptophan were added to the NR dispersion. As noted in Fig. 5(b), a gradual decrease in the intensity of Tb<sup>3+</sup> emission is observed with an increase in the concentration of tryptophan in the dispersion. Almost a 90% reduction in the emission intensity of Tb<sup>3+</sup> is observed with the addition of 5 mM tryptophan. In the excitation spectra of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup>, a shift towards the higher wavelength (redshift) is observed for the characteristic tryptophan peak at higher concentrations of tryptophan (Fig. 5(a)). The redshift observed in the excitation spectra of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs can be attributed to the tryptophan binding to the OA present on the surface of the NRs. This likely alters the energy level of the OA, thus affecting the



Fig. 4 Bar diagram showing (a) the effect of different amino acids on the PL intensity of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs, (b) the effect of different metal ions on the PL intensity of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs, and (c) the interference of other amino acids on the selective detection of tryptophan using OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods, and (d) the interference of metal ions on the selective detection of tryptophan using OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods. The concentration of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods in DMSO used was 1 mg per 10 mL.

energy transfer efficiency between OA and Tb<sup>3+</sup> ions present in the nanorods.<sup>60–62</sup>

The sensitivity of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs towards the detection of tryptophan ions was evaluated using the Stern–Volmer analysis, which relates the luminescence intensity of the nanorods in the presence of an analyte to its intensity in its absence. In the following Stern–Volmer equation (eqn (2)):

$$I_0/I = 1 + K_{SV}[C] \quad (2)$$

$I_0$  and  $I$  denote the luminescence intensity of the nanorods before and after the addition of tryptophan ions, respectively.<sup>63</sup> The quenching constant,  $K_{SV}$ , was determined from the plot of luminescence intensity ratio vs. concentration of tryptophan. The resulting graph showed good linearity from 100 nM to 10  $\mu$ M (Fig. 6)

### Tryptophan detection in biological samples

The detection of tryptophan using OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs is extended to biological samples like human blood plasma, saliva, and urine specimens. The determination of tryptophan in clinical specimens is essential, though challenging, given the presence of heterogeneous organic (proteins) and inorganic (for example, metal ions) components.<sup>64</sup> To assess the tryptophan level in blood plasma, we have taken a 2 mL dispersion of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs and added 100  $\mu$ L of pure plasma. The PL analysis of the mixture shows quenching of the luminescence intensity of Tb<sup>3+</sup> ions in OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs (Fig. 6). The limit of detection (LOD) is determined using the equation  $3\sigma/K$ , where  $\sigma$  is the standard deviation of the blank and  $K$  is the slope of the calibration plot. The calculated LOD is 0.61  $\mu$ M.



Fig. 5 Excitation (a) and PL (b) spectra of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs collected with the gradual addition of tryptophan solutions of increasing concentration. The concentration of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods in DMSO used was 1 mg per 10 mL.



Fig. 6 The Stern–Volmer plot of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs (3%) with the addition of increasing concentrations of tryptophan in DMSO. The concentration of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods in DMSO used is 1 mg per 10 mL.

To check the effectiveness of our approach, a mixed solution of amino acids (2 mmol each), except tryptophan, was added to the above mixture containing NRs and blood plasma. The corresponding dispersion shows no further quenching. Next, the NR dispersion is mixed with pure plasma containing a mixture of amino acids, including tryptophan (2 mmol). The corresponding PL spectrum shows a further reduction in the emission intensity of Tb<sup>3+</sup> ions (Fig. 7(a)). The above results suggest that the reduction in the emission intensity from the NRs is caused primarily by the presence of tryptophan in the dispersion.

Furthermore, a detection analysis was performed on the plasma sample after removing the proteins to detect the pres-

ence of free tryptophan in the blood plasma. A 100  $\mu$ L deproteinated plasma sample was added to a 2 mL dispersion of NRs. The PL spectrum of the resulting sample shows a reduction in the luminescence intensity of Tb<sup>3+</sup> ions in OA@CaSO<sub>4</sub>:Tb<sup>3+</sup>. However, the quenching observed was relatively lower than that observed for pure plasma samples, primarily due to the absence of tryptophan bound to plasma proteins (Fig. 7(b)). Again, a sample of deproteinated blood plasma and the mixture of amino acids (2 mmol each), except tryptophan, was added to the NR dispersion. Again, no further quenching of the emission intensity is observed. Finally, the NR dispersion was treated with a sample of deproteinated blood plasma with a mixture of amino acids, including tryptophan (2 mmol each). In this case, further quenching was observed, confirming the efficiency of our method in detecting tryptophan in human blood plasma.

The above results motivated us to extend the study to detect tryptophan in human saliva and urine. We followed a procedure similar to that performed with the blood plasma study. In this case, saliva and urine samples were used directly without further processing. In both studies, the PL analysis showed considerable quenching of the luminescence intensity of Tb<sup>3+</sup> ions in OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs. Similarly, the NR dispersion with the saliva and urine samples, with a mixture of amino acids (2 mmol each), except tryptophan, shows hardly any quenching (Fig. 7(c & d)). The addition of a mixture containing all the amino acids, including tryptophan (2 mmol), to the saliva and urine samples in the NR solution resulted in further quenching of the Tb<sup>3+</sup> emission intensity. These results suggest that OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs could be an efficient optical probe for detecting tryptophan in biological samples without much interference from other analytes. In addition to the emission spectra, we also tried to study the excitation spectra at  $\lambda_{em} = 542$  nm after the addition of pure plasma to the OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs, and the same in the presence of an



**Fig. 7** PL analysis: (a) emission spectra of pure  $\text{OA@CaSO}_4\text{:Tb}^{3+}$  NRs, after addition of pure blood plasma sample, pure blood plasma sample with a mixture of amino acids without tryptophan, and pure sample with a mixture of amino acids including tryptophan to  $\text{OA@CaSO}_4\text{:Tb}^{3+}$  NRs; (b) emission spectra of pure  $\text{OA@CaSO}_4\text{:Tb}^{3+}$  NRs, after addition of deproteinized blood plasma sample, deproteinized sample with a mixture of amino acids without tryptophan, and deproteinized sample with a mixture of amino acids including tryptophan to  $\text{OA@CaSO}_4\text{:Tb}^{3+}$  NRs; (c) emission spectra of pure  $\text{OA@CaSO}_4\text{:Tb}^{3+}$  NRs, after addition of saliva, a saliva sample with a mixture of amino acids without tryptophan, and saliva with a mixture of amino acids including tryptophan to  $\text{OA@CaSO}_4\text{:Tb}^{3+}$  NRs; and (d) emission spectra of pure  $\text{OA@CaSO}_4\text{:Tb}^{3+}$  NRs, after addition of a urine sample, a urine sample with a mixture of amino acids without tryptophan, and a urine sample with a mixture of amino acids including tryptophan to  $\text{OA@CaSO}_4\text{:Tb}^{3+}$  NRs. The concentration of  $\text{OA@CaSO}_4\text{:Tb}^{3+}$  nanorods in DMSO is 1 mg per 10 mL.

additional 2 mmol concentration of tryptophan (Fig. S7, ESI†). It is noted that the excitation peaks showed a similar shift, as noted in the case of the addition of different concentrations of tryptophan in NRs (*vide supra*). Additionally, the results of the recovery test of tryptophan in the bio-related samples are shown in Table 1. The results showed that recoveries of tryptophan in these samples are within the range of 99–102.5%.

#### Proposed detection mechanism

To investigate the cause of the quenching of  $\text{Tb}^{3+}$  ion emission intensity upon the addition of tryptophan, some additional experiments and analyses were performed. The attachment or interaction of tryptophan with OA present on the surface of

$\text{OA@CaSO}_4\text{:Tb}^{3+}$  nanorods was validated through FTIR analysis. The FTIR spectrum shows a shift in the N–H bond stretching to a lower wavenumber (from  $3400\text{ cm}^{-1}$  to  $3130\text{ cm}^{-1}$ ) for the  $\text{OA@CaSO}_4\text{:Tb}^{3+}$  NRs after the addition of tryptophan (Fig. S8, ESI†). This indicates a probable tryptophan binding to the OA on the NR surface through the pyrimidine N–H-group. Furthermore, to confirm any possible interaction between the amino acid tryptophan and OA, NMR analysis was performed. First, the  $^1\text{H}$  NMR spectra of tryptophan and OA were recorded in  $\text{DMSO-d}_6$ . The  $^1\text{H}$  NMR spectrum of tryptophan consists of 3 peaks within the 3 to 3.5 ppm range, which belongs to the aliphatic C–H bonds (Fig. S9, ESI†). Similarly, OA shows a peak at 6 ppm corresponding to the  $\text{sp}^2$

**Table 1** Determination of spiked tryptophan in bio-related samples

| Tryptophan added to samples | Amount added (mmol) | Calculated <sup>a</sup> (mmol) | Standard error | Coefficient of variance | Recovery (%) |
|-----------------------------|---------------------|--------------------------------|----------------|-------------------------|--------------|
| Pure blood plasma           | 2                   | 1.98                           | 0.2            | 0.10                    | 99           |
| Deproteinized blood plasma  | 2                   | 2.01                           | 0.3            | 0.14                    | 100.5        |
| Saliva                      | 2                   | 2.05                           | 0.6            | 0.29                    | 102.5        |
| Urine                       | 2                   | 2.02                           | 0.5            | 0.24                    | 101          |

<sup>a</sup> Mean of three determinations.

C–H unit. The peaks at 11.33 and 10.89 ppm represent the two N–H bonds of OA (Fig. S10, ESI†). In a separate experiment, a few drops of tryptophan were mixed with a DMSO-d<sub>6</sub> solution containing OA. The NMR spectrum of the mixture shows a shift in the peak position in the aliphatic region of tryptophan (Fig. S11, ESI†). We believe that this shift is because of the interaction of tryptophan's amino and –COOH groups with OA. This interaction likely resulted in a change in the electron density around the carbon of the tryptophan molecules, causing a shift in the chemical shift positions of these hydrogen atoms of the aliphatic regions of tryptophan. The concentration of OA is much greater than that of tryptophan in the above experiment. As a result, only the shift in tryptophan protons is observed. To acquire more information, a <sup>1</sup>H NMR spectrum was recorded for a solution containing a 1 : 1 molar ratio of tryptophan and OA in DMSO-d<sub>6</sub> (Fig. S12, ESI†). Interestingly, a shift in the peak positions of both OA and tryptophan is noted, suggesting a chemical interaction between both molecules. This interaction is likely to cause changes in the triplet state of the OA, thereby decreasing the probability of energy transfer from OA to Tb<sup>3+</sup> ions present inside the NRs.

The decrease in the energy transfer probability from OA to Tb<sup>3+</sup> inside the NRs reduces the excited state population of Tb<sup>3+</sup> ions, decreasing the emission intensity. This is validated by the reduction in the lifetime of the <sup>5</sup>D<sub>0</sub> level of Tb<sup>3+</sup> ions in OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs, shifting from 2.00 ms to 0.01 ms after the addition of tryptophan. In contrast, minimal change was observed in the case of serine addition (2.00 ms to 1.99 ms). These dynamics are illustrated in Fig. 8. The decrease in lifetimes indicates the presence of another relaxation pathway that can depopulate the excited state. The potential role of  $\pi$ – $\pi$  interactions, whereby tryptophan engages with the aromatic systems in the nanorods, is also noteworthy and could contribute to luminescence quenching by perturbing electronic transitions responsible for the emission.<sup>65–70</sup>

To further check any competitive absorption occurring between OA and tryptophan for the excitation energy, UV-vis absorption analysis was performed. The UV-vis spectra shown in Fig. S13† show a clear overlap between the absorption peaks of OA and tryptophan (between 250 nm to 300 nm). However, near 290 nm, the absorbance is higher for OA compared to tryptophan. This suggests that there is competitive absorption to some extent between OA and tryptophan for the excitation light. Thus, part of the reduction in the Tb<sup>3+</sup> emission intensity in the presence of tryptophan is likely due to the competi-



**Fig. 8** The lifetime decay curves of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> NRs before (blue) and after the addition of serine (red) and tryptophan (green). The concentration of OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> nanorods in DMSO was 1 mg per 10 mL.

tive absorption. Therefore, one of the reasons for the observed reduction in the emission intensity of Tb<sup>3+</sup> ions upon the addition of tryptophan could be the combination of competitive absorption of excitation energy between OA@CaSO<sub>4</sub>:Tb<sup>3+</sup> and tryptophan. In addition, intermolecular interactions between the OA capping agent and tryptophan alter the energy of the triplet state, thereby reducing the probability of energy transfer efficiency between OA and Tb<sup>3+</sup> present inside the nanorods.

## Conclusions

In summary, we utilized a microwave synthesis method to prepare OA-capped Tb<sup>3+</sup>-doped CaSO<sub>4</sub> colloidal nanorods. When excited at the OA absorption wavelength of 291 nm, these colloidal nanorods exhibited strong emissions at 542 nm along with weak emissions at 488, 585, and 620 nm, which are characteristic emission peaks of Tb<sup>3+</sup> ions. The addition of tryptophan selectively quenches the emission intensities of the Tb<sup>3+</sup> ions due to a reduction in the energy transfer efficiency between OA and Tb<sup>3+</sup> ions, presumably caused by the overlapping of tryptophan emission with that of OA along with the chemical interaction between OA and tryptophan altering the

energy transfer efficiency between OA and Tb<sup>3+</sup> ions. This quenching effect is specific to tryptophan, as adding other amino acids and analytes had little impact on the Tb<sup>3+</sup> ion emission intensity. In addition, the developed nanorods efficiently detect tryptophan in human blood plasma, saliva, and urine, indicating its potential use in biomedical applications.

## Author contributions

J. Kumar and H. V. S. R. M. Koppiseti conducted a critical analysis of experimental data. J. Kumar contributed to the writing of the manuscript. N. Yadav helped with biological experiments. V. Mishra assisted with the synthesis. A. Roy and A. Mitra assisted with the physical characterizations and NMR analyses, respectively. V. Mahalingam planned the study, providing motivation and oversight throughout its execution.

## Data availability

The data that support the findings of this study are available from the corresponding author (Venkataramanan Mahalingam) upon reasonable request.

## Conflicts of interest

The authors have no conflicts to declare neither in the financial interests nor in the personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgements

VM thanks SERB, CSIR, and IISER Kolkata for providing the instrumental facilities and funding. The authors thank DST-FIST for the TEM facility at IISER Kolkata through the project SR/FST/CS11-029/2014. JK thanks his family for their encouragement and support.

## References

- 1 A. Agazzi, F. De Ponti, R. De Giorgio, S. M. Candura, L. Anselmi, E. Cervio, A. Di Nucci and M. Tonini, *Dig. Liver Dis.*, 2003, **35**, 590–595.
- 2 L. Palego, L. Betti, A. Rossi and G. Giannaccini, *J. Amino Acids*, 2016, **2016**, 1–13.
- 3 D. M. Richard, M. A. Dawes, C. W. Mathias, A. Acheson, N. Hill-Kapturczak and D. M. Dougherty, *Int. J. Tryptophan Res.*, 2009, **2**, 45.
- 4 A. A. B. Badawy, *Biosci. Rep.*, 2022, **42**, 20221682.
- 5 Y. Chen, J. Chen, D. Guo, P. Yang, S. Chen, C. Zhao, C. Xu, Q. Zhang, C. Lin, S. Zhong and S. Zhang, *Front. Oncol.*, 2022, **12**, 800291.
- 6 D. L. Head and C. G. McCarty, *Tetrahedron Lett.*, 1973, **14**, 1405–1408.
- 7 J. D. Fernstrom and R. J. Wurtman, *Science*, 1971, **173**, 149–152.
- 8 T. Chen, X. Zheng, X. Ma, Y. Bao, Y. Ni, C. Hu, C. Rajani, F. Huang, A. Zhao, W. Jiia and W. Jia, *PLoS One*, 2016, **11**, e0162192.
- 9 A. Coppen, E. G. Eccleston and M. Peet, *Lancet*, 1973, **302**, 60–63.
- 10 A. B. Badawy, *J. Psychopharmacol.*, 2010, **24**, 809–815.
- 11 S. Ogawa, T. Fujii, N. Koga, H. Hori, T. Teraishi, K. Hattori, T. Noda, T. Higuchi, N. Motohashi and H. Kunugi, *J. Clin. Psychiatry*, 2014, **75**, e906–e915.
- 12 R. J. Porter, P. Gallagher and J. T. O'Brien, *J. Psychopharmacol.*, 2007, **21**, 71–75.
- 13 K. Vielhaber, D. Riemann, B. Feige, A. Kuelz, C. Kirschbaum and U. Voderholzer, *Pharmacopsychiatry*, 2005, **38**, 87–94.
- 14 G. Lindseth, B. Helland and J. Caspers, *Arch. Psychiatr. Nurs.*, 2015, **29**, 102.
- 15 J. K. Yeh and R. R. Brown, *J. Nutr.*, 1977, **107**, 261–271.
- 16 H. L. Davis Jr, R. R. Brown, J. Leklem and I. H. Carlson, *Cancer*, 1973, **31**, 1061–1064.
- 17 J. S. Ward, D. J. Lapworth, D. S. Read, S. Pedley, S. T. Banda, M. Monjerezi and A. M. MacDonald, *Sci. Total Environ.*, 2021, **750**, 141284.
- 18 C. E. Garner, S. Smith, B. de Lacy Costello, P. White, R. Spencer, C. S. J. Probert and N. M. Ratcliffem, *FASEB J.*, 2007, **21**, 1675–1688.
- 19 I. A. Ratiu, V. Bocos-Bintintan, F. Monedeiro, M. Milanowski, T. Ligor and B. Buszewski, *Crit. Rev. Anal. Chem.*, 2020, **50**, 501–512.
- 20 J. W. Sam, X. J. Tang and J. Peisach, *J. Am. Chem. Soc.*, 1994, **116**, 5250–5256.
- 21 S. E. Jackson, N. J. Pearson, W. L. Griffin and E. A. Belousova, *Chem. Geol.*, 2004, **211**, 47–69.
- 22 J. Dedina and D. L. Tsalev, *Hydride Generation Atomic Absorption Spectrometry*, Wiley, 1995, vol. 130, p. 526.
- 23 P. W. J. M. Boumans, *Fresenius' Z. Anal. Chem.*, 1979, **299**, 337–361.
- 24 G. Dantelle, M. Matulionyte, D. Testemale, A. Cantarano, A. Ibanez and F. Vetrone, *Phys. Chem. Chem. Phys.*, 2019, **21**, 11132–11141.
- 25 K. Saidi, M. Yangui, C. Hernández-Álvarez, M. Dammak, I. Rafael Martín Benenzuela and M. Runowski, *ACS Appl. Mater. Interfaces*, 2024, **16**, 19137–19149.
- 26 B. B. S. Ramin, W. G. Santos, Y. Messaddeq, E. Deffune, M. L. Moraes and S. J. L. Ribeiro, *J. Lumin.*, 2024, **271**, 120590.
- 27 J.-C. Boyer and F. C. J. M. van Veggel, *Nanoscale*, 2010, **2**, 1417.
- 28 R. Zhang, L. X. Wang, Y. Di Zhang, C. H. Ge, J. P. Wang, Y. Zhang and X. D. Zhang, *J. Fluoresc.*, 2018, **28**, 439–444.
- 29 B. S. Naidu, B. Vishwanadh, V. Sudarsan and R. K. Vatsa, *Dalton Trans.*, 2012, **41**, 3194–3203.
- 30 S. Pang, Z. Zhou and Q. Wang, *J. Nanopart. Res.*, 2013, **15**, 1–9.

- 31 U. Hömmerich, E. E. Nyein, D. S. Lee, A. J. Steckl and J. M. Zavada, *Appl. Phys. Lett.*, 2003, **83**, 4556–4558.
- 32 B. Joo Han Kim, P. H. Holloway, P. H. Holloway and P. Holloway, *Adv. Mater.*, 2005, **17**, 91–96.
- 33 D. A. Hirsh, N. J. J. Johnson, F. C. J. M. Van Veggel and R. W. Schurko, *Chem. Mater.*, 2015, **27**, 6495–6507.
- 34 J. M. Gonçalves, A. R. N. Bastos, S. J. L. Ribeiro, L. D. Carlos, R. L. Longo, J. M. A. Caiut and R. A. S. Ferreira, *Nanoscale Adv.*, 2024, **6**, 1486.
- 35 J. C. G. Bünzli and C. Piguet, *Chem. Soc. Rev.*, 2005, **34**, 1048–1077.
- 36 J. G. Jesu Raj, M. Quintanilla, K. A. Mahmoud, A. Ng, F. Vetrone and M. Zourob, *ACS Appl. Mater. Interfaces*, 2015, **7**, 18257–18265.
- 37 D. Sarkar, S. Ganguli, T. Samanta and V. Mahalingam, *Langmuir*, 2019, **35**, 6211–6230.
- 38 R. Z. Wu, X. Yang, L. W. Zhang and P. P. Zhou, *Dalton Trans.*, 2017, **46**, 9859–9867.
- 39 *Luminescence of lanthanide ions in coordination compounds and nanomaterials*, ed. A. de Bettencourt-Dias, John Wiley & Sons, 2014.
- 40 Q. Li, C. Wang, H. Tan, G. Tang, J. Gao and C. H. Chen, *RSC Adv.*, 2016, **6**, 17811–17817.
- 41 R. Lv, M. Raab, Y. Wang, J. Tian, J. Lin and P. N. Prasad, *Coord. Chem. Rev.*, 2022, **460**, 214486.
- 42 M. Chatti, S. Sarkar and V. Mahalingam, *Microchim. Acta*, 2016, **183**, 133–140.
- 43 K. J. Barnham, C. L. Masters and A. I. Bush, *Nat. Rev. Drug Discovery*, 2004, **3**, 205–214.
- 44 Z. Liu, Z. Ju, H. Liu, Z. Wang and R. Lv, *J. Innovative Opt. Health Sci.*, 2024, 2441002.
- 45 H. Shao, D. Xu, Y. Ding, X. Hong and Y. Liu, *Microchim. Acta*, 2018, **185**, 1–8.
- 46 B. Li, A. A. Ansari, A. K. Parchur and R. Lv, *Coord. Chem. Rev.*, 2024, **514**, 215922.
- 47 S. Sarkar, M. Chatti and V. Mahalingam, *Chem. – Eur. J.*, 2014, **20**, 3311–3316.
- 48 S. Sarkar, M. Chatti, V. N. K. B. Adusumalli and V. Mahalingam, *ACS Appl. Mater. Interfaces*, 2015, **7**, 25702–25708.
- 49 C. Lv, W. Di, Z. Liu, K. Zheng and W. Qin, *Analyst*, 2014, **139**, 4547–4555.
- 50 B. Meesaragandla, A. Verma, V. Bheemireddy and V. Mahalingam, *ChemistrySelect*, 2016, **1**, 4927–4934.
- 51 C. Hazra, T. Samanta and V. Mahalingam, *J. Mater. Chem. C*, 2014, **2**, 10157–10163.
- 52 R. Krishnan, S. N. Shibu, D. Poelman, A. K. Badyal, A. K. Kunti, H. C. Swart and S. G. Menon, *Mater. Today Commun.*, 2022, **32**, 103890.
- 53 Y. Deguchi, M. Kono, Y. Koizumi, Y. I. Izato and A. Miyake, *Org. Process Res. Dev.*, 2020, **24**, 1614–1620.
- 54 T. Fujii, H. Ohfuji and T. Inoue, *Phys. Chem. Miner.*, 2016, **43**, 353–361.
- 55 H. J. K. Kim, K. E. Kaplan, P. Schindler, S. Xu, M. M. Winterkorn, D. B. Heinz, T. S. English, J. Provine, F. B. Prinz and T. W. Kenny, *ACS Appl. Mater. Interfaces*, 2019, **11**, 9594–9599.
- 56 F. Schiffmann, J. Vandevondele, J. Hutter, R. Wirz, A. Urakawa and A. Baiker, *J. Phys. Chem. C*, 2010, **114**, 8398–8404.
- 57 A. P. Bassett, S. W. Magennis, P. B. Glover, D. J. Lewis, N. Spencer, S. Parsons, R. M. Williams, L. De Cola and Z. Pikramenou, *J. Am. Chem. Soc.*, 2004, **126**, 9413–9424.
- 58 C. Hazra, T. Samanta, A. V. Asaithambi and V. Mahalingam, *Dalton Trans.*, 2014, **43**, 6623–6630.
- 59 R. F. Chen, *Anal. Lett.*, 1967, **1**, 35–42.
- 60 C. P. Pan, P. L. Muino, M. D. Barkley and P. R. Callis, *J. Phys. Chem. B*, 2011, **115**, 3245–3253.
- 61 D. M. Uriza-Prias, A. Méndez-Blas and J. F. Rivas-Silva, *Open J. Phys. Chem.*, 2021, **11**, 87–105.
- 62 J. T. Vivian and P. R. Callis, *Biophys. J.*, 2001, **80**, 2093–2109.
- 63 R. Krishnan, S. N. Shibu, D. Poelman, A. K. Badyal, A. K. Kunti, H. C. Swart and S. G. Menon, *Mater. Today Commun.*, 2022, **32**, 103890.
- 64 R. W. Yip, W. D. Riddell and A. G. Szabo, *Can. J. Chem.*, 1970, **48**, 987–999.
- 65 C. Q. Jiao, M. Sun, F. Liu, Y. N. Zhou, Y. Y. Zhu, Z. G. Sun and J. Li, *ACS Omega*, 2018, **3**, 16735–16742.
- 66 Y. Zhou and J. Yoon, *Chem. Soc.*, 2012, **41**, 52–67.
- 67 C. He, J. Wang, P. Wu, L. Jia, Y. Bai, Z. Zhang and C. Duan, *Chem. Commun.*, 2012, **48**, 11880–11882.
- 68 Z. Zhao, D. Yang, B. Xing, C. Ma, Z. G. Sun, Y. Y. Zhu, H. Y. Li and J. Li, *RSC Adv.*, 2016, **6**, 92175–92185.
- 69 H. Tsukube, M. Wada, S. Shinoda and H. Tamiaki, *Chem. Commun.*, 1999, **11**, 1007–1008.
- 70 C. Q. Jiao, M. Sun, F. Liu, Y. N. Zhou, Y. Y. Zhu, Z. G. Sun and J. Li, *ACS Omega*, 2018, **3**, 16735–16742.